Navigation Links
Specialty European Pharma launches plenaxis in Germany
Date:2/26/2008

London, 26 February. Speciality European Pharma (SEP) today announced the launch of Plenaxis® in Germany. Plenaxis® is used to treat advanced and metastatic hormone responsive prostate cancer and it causes a rapid and sustained decline in testosterone levels, thereby giving quick control of prostate cancer symptoms. Once the disease is under control, the physician can choose to either keep the patient on Plenaxis® or to stop treatment and recommence once there is evidence of disease activity returning. This is attractive because, on stopping treatment with Plenaxis® the patients testosterone levels will return to the normal range whilst the disease remains under control. In addition to the quick control of testosterone, Plenaxis avoids any testosterone flare and removes the need for concomitant use of anti-androgen therapy.

Commenting on the launch of Plenaxis®, Geoff McMillan, the CEO of SEP, said, Plenaxis® is an important product, both for SEP and for sufferers of prostate cancer. Plenaxis is the first new type of hormone treatment for prostate cancer to be introduced for many years and it gives patients and physicians added control of this disease.

Ken Watters, Chief Medical Officer of SEP added that prostate cancer is an important cause of morbidity and mortality in males over 50 years old. The emerging treatment modalities are especially suited to Plenaxis® with its rapid and sustained disease control and quick testosterone recovery.


'/>"/>

Contact: Blake Scotland
bscotland@ruderfinn.co.uk
020-746-28975
Ruder Finn Public Relations
Source:Eurekalert

Page: 1

Related medicine news :

1. Darwin Enters into Marketing Partnership with Agency Specialty Product Network
2. MarketResearch.com Distributes Key Findings on Global Specialty Medical Beds and Therapeutic Surfaces Market
3. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
4. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
5. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
6. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
7. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
8. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
9. Albemarle Raises Prices of Specialty Aluminas
10. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
11. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, ... & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of proactive ... with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance ... a new charity drive to generate community support for efforts to educate the local ... and treatments for all types of cancer. , Each day in America, roughly ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore ... to communities in east Texas, is launching a regional charity effort to provide ... in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... of highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, ... hormone imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... 17, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... and non-U.S. investors for the sale of shares ... the Company,s newly designated Series B Convertible Preferred ... expects to conduct a closing with respect to ...
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
Breaking Medicine Technology: